je.st
news
Tag: merck
Merck Animal Health Receives FDA Approval of Safe-Guard AquaSol for Use in Swine
2016-08-05 02:00:00| ThePigSite - Industry News
US - Merck Animal Health (known as MSD Animal Health outside of the United States and Canada) today announced the introduction of Safe-Guard® AquaSol (fenbendazole oral suspension) for use in U.S. swine operations.
Tags: use
health
animal
approval
Merck Animal Health receives FDA approval of Safe-Guard AquaSol for use in swine
2016-08-04 06:00:00| National Hog Farmer
Merck Animal Health today announced the introduction of Safe-Guard AquaSol (fenbendazole oral suspension) for use in U.S. swine operations. Safe-Guard AquaSol is indicated for the treatment and control of adult and larval stages of large roundworms, whipworms and kidney worms, as well as adult stages of the small stomach worm, nodular worm and lungworm. read more
Tags: use
health
animal
approval
Merck Announces Second-Quarter 2016 Financial Results
2016-07-29 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77 Advanced KEYTRUDA Development Program KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces Fourth-Quarter 2016 Dividend
2016-07-26 18:50:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the companys common stock for the fourth quarter of 2016. Payment will be made on Oct. 7, 2016 to shareholders of record at the close of business on Sept. 15, 2016. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces fourthquarter
Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
2016-07-25 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced two regulatory milestones for the companys investigational vaccine for Ebola Zaire, V920 (rVSVG-ZEBOV-GP, live attenuated): the U.S. Food and Drug Administration (FDA) has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) status. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: status
prime
therapy
receives
Sites : [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] next »